FILTER
LATEST INTERVIEWS
Alan Rubino
CEO, EMISPHERE TECHNOLOGIES
Emisphere Technologies is a leading company in converting injectable therapeutics into advanced oral formulations.
Stephen Wang & Ryan Yoder
CHAIRMAN and CEO & VP BUSINESS DEVELOPMENT, KINGCHEM LIFE SCIENCE
Kingchem provides contract development and manufacturing services to the pharmaceutical and chemical industries.
Karen Fallen
SENIOR VICE PRESIDENT: BUSINESS UNIT HEAD - CLINICAL DEVELOPMENT & MANUFACTURING, LONZA
Lonza is one of the world's leading suppliers to the pharma, biotech and specialty ingredient markets.
Shabbir Dahod
PRESIDENT AND CEO, TRACELINK
TraceLink is the world’s largest integrated digital supply network connecting the life sciences supply chain.
Peter Hall
CEO, AUSTRALIAN DRILLING INDUSTRY ASSOCIATION (ADIA)
The Australian Drilling Industry Association (ADIA) is a not-for-profit organization representing the drilling industry nationally.
Christiana Goh Bardon
MD, MBA, MANAGING DIRECTOR, UBS ONCOLOGY IMPACT FUND MANAGED BY MPM CAPITAL & PORTFOLIO MANAGER, BURRAGE CAPITAL FUND
UBS Oncology Impact Fund is an evergreen fund specializing in investments in early stage oncology and cancer therapeutics.
Ted Moses O.Q
President, SAENCAT
The Secretariat promotes sustainable relations and socio-economic alliances across the region to foster harmonious development.
Steve Dixon
CEO, STRACON
STRACON provides mining services in Peru and Latin America, covering all the stages of a mining project.
John Downing & Ian Mitchell
CEO & GENERAL MANAGER, DOWNING TEAL
Formed in 1966, Downing Teal is a Perth-based employment services firm.
Danilo Veras
CCO, PORT OF SANTOS
The Port of Santos is the largest port in Latin America and is working to attract more clients in the chemicals industry.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
